Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway |
| |
| Authors: | Maolan Li Fei Zhang Xu'an Wang Xiangsong Wu Bingtai Zhang Ning Zhang Wenguang Wu Zheng Wang Hao Weng Shibo Liu Guofeng Gao Jiasheng Mu Yijun Shu Runfa Bao Yang Cao Jianhua Lu Jun Gu Jian Zhu Yingbin Liu |
| |
| Affiliation: | 1. Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong, University School of Medicine, Shanghai, China;2. Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong, University School of Medicine, Shanghai, China;3. Institute of Biliary Tract Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, China;4. Department of General Surgery, Shanxi Medical University Second Hospital, Taiyuan, China |
| |
| Abstract: | Magnolol, the major active compound found in Magnolia officinalis has a wide range of clinical applications due to its anti‐inflammation and anti‐oxidation effects. This study investigated the effects of magnolol on the growth of human gallbladder carcinoma (GBC) cell lines. The results indicated that magnolol could significantly inhibit the growth of GBC cell lines in a dose‐ and time‐dependent manner. Magnolol also blocked cell cycle progression at G0/G1 phase and induced mitochondrial‐related apoptosis by upregulating p53 and p21 protein levels and by downregulating cyclin D1, CDC25A, and Cdk2 protein levels. When cells were pretreated with a p53 inhibitor (pifithrin‐a), followed by magnolol treatment, pifithrin‐a blocked magnolol‐induced apoptosis and G0/G1 arrest. In vivo, magnolol suppressed tumor growth and activated the same mechanisms as were activated in vitro. In conclusion, our study is the first to report that magnolol has an inhibitory effect on the growth of GBC cells and that this compound may have potential as a novel therapeutic agent for the treatment of GBC. |
| |
| Keywords: | Apoptosis cell cycle arrest gallbladder carcinoma magnolol p53 pathways |
|
|
